Jan 11, 2023 / 07:15PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the conference today with Alkermes. As you guys probably know, we're not switching for Q&A this year. If you want to ask a question during the Q&A session, just raise your hand, someone will bring you a microphone or alternatively, you can submit them electronically and I'll read them off the iPad. So with that, let me turn it over to Alkermes CEO, Richard Pops, for the presentation.
Richard F. Pops - Alkermes plc - Chairman & CEO
Thank you, Jess. Good morning, everyone. So it's slightly different this year. The way we're approaching this presentation. The title of this year's presentation is a clear investment thesis. So what you're going to see, I hope, is how we've evolved the business to reveal what we see as a very straightforward path that creating value for shareholders. Our Neuroscience business represents a compelling opportunity with topline growth drivers and
Alkermes Plc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers